First Time Loading...

China Resources Boya Bio pharmaceutical Group Co Ltd
SZSE:300294

Watchlist Manager
China Resources Boya Bio pharmaceutical Group Co Ltd Logo
China Resources Boya Bio pharmaceutical Group Co Ltd
SZSE:300294
Watchlist
Price: 31.28 CNY -0.29% Market Closed
Updated: Apr 29, 2024

China Resources Boya Bio pharmaceutical Group Co Ltd
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

China Resources Boya Bio pharmaceutical Group Co Ltd
Operating Income Peer Comparison

Comparables:
6160
1801
603392
300122
300896

Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
China Resources Boya Bio pharmaceutical Group Co Ltd
SZSE:300294
Operating Income
¥549.8m
CAGR 3-Years
18%
CAGR 5-Years
0%
CAGR 10-Years
22%
Beigene Ltd
HKEX:6160
Operating Income
-¥12B
CAGR 3-Years
-21%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Operating Income
-¥1.1B
CAGR 3-Years
-36%
CAGR 5-Years
6%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Operating Income
¥1.4B
CAGR 3-Years
22%
CAGR 5-Years
55%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Operating Income
¥9.9B
CAGR 3-Years
38%
CAGR 5-Years
46%
CAGR 10-Years
47%
Imeik Technology Development Co Ltd
SZSE:300896
Operating Income
¥1.4B
CAGR 3-Years
59%
CAGR 5-Years
72%
CAGR 10-Years
N/A

See Also

What is China Resources Boya Bio pharmaceutical Group Co Ltd's Operating Income?
Operating Income
549.8m CNY

Based on the financial report for Dec 31, 2023, China Resources Boya Bio pharmaceutical Group Co Ltd's Operating Income amounts to 549.8m CNY.

What is China Resources Boya Bio pharmaceutical Group Co Ltd's Operating Income growth rate?
Operating Income CAGR 10Y
22%

Over the last year, the Operating Income growth was 7%. The average annual Operating Income growth rates for China Resources Boya Bio pharmaceutical Group Co Ltd have been 18% over the past three years , and 22% over the past ten years .